pathophysiolog
lung
diseas
complex
proteolyt
enzym
may
play
role
could
use
biomark
review
literatur
search
make
overview
known
express
prolinespecif
peptidas
dipeptidyl
peptidas
dpp
prolyl
oligopeptidas
prep
fibroblast
activ
protein
fap
healthi
diseas
lung
search
term
includ
asthma
chronic
obstruct
pulmonari
diseas
copd
lung
cancer
fibrosi
ischemia
reperfus
injuri
pneumonia
knowledg
loss
gain
protein
express
activ
diseas
might
tie
enzym
certain
cell
type
substrat
interact
partner
involv
pathophysiolog
diseas
ultim
lead
elucid
function
role
potenti
therapeut
target
data
could
found
enzym
less
explor
publish
data
howev
often
appear
conflict
appli
method
diver
specif
assay
use
question
conclus
inform
express
prolinespecif
peptidas
healthi
diseas
lung
lack
beg
welldesign
research
keyword
dipeptidyl
peptidas
dipeptidyl
peptidas
dipeptidyl
peptidas
fibroblast
activ
protein
fap
lung
prolyl
oligopeptidas
prep
sever
respiratori
diseas
lead
caus
death
form
burden
mani
exampl
around
million
peopl
suffer
asthma
lung
cancer
top
caus
cancerrel
death
pathophysiolog
underli
lung
diseas
complex
proteolyt
enzym
may
involv
could
serv
potenti
biomark
review
focus
sever
member
prolyl
oligopeptidas
prep
famili
famili
name
prep
ec
dipeptidyl
peptidas
ec
dipeptidyl
peptidas
dipeptidyl
peptidas
fibroblast
activ
protein
fap
ec
express
lung
enzym
serin
proteas
uniqu
abil
cleav
peptid
bond
prolin
classif
famili
highlight
structur
conserv
crystal
structur
avail
fap
prep
model
structur
publish
also
known
adenosin
deaminas
bind
protein
origin
describ
dpp
activ
mean
cleav
dipeptid
free
aminoterminu
preferenti
pro
ala
penultim
posit
express
type
ii
transmembran
protein
also
solubl
form
detect
bodi
fluid
sourc
circul
fulli
known
bone
marrow
cell
adipocyt
skelet
muscl
cell
vascular
smooth
muscl
cell
implic
sever
proteas
matrix
metalloproteas
abl
induc
shed
plasma
membran
widespread
tissu
distribut
abund
kidney
small
intestin
besid
express
epitheli
endotheli
cell
also
found
multipl
cell
immun
system
mani
substrat
alreadi
identifi
amongst
neuropeptid
chemokin
incretin
hormon
glucagonlik
peptid
glp
gastric
inhibitori
polypeptid
gip
latter
wellknown
sinc
clinic
use
treat
type
diabet
prolong
biolog
activ
incretin
besid
enzymat
function
abl
interact
molecul
adenosin
deaminas
mannos
growth
factor
ii
receptor
sodium
hydrogen
exchang
type
protein
extracellular
matrix
howev
last
interact
might
indirect
identifi
similar
lack
transmembran
region
secret
signal
led
conclus
locat
cytoplasm
multipl
isoform
shown
long
isoform
longer
nterminu
contain
nuclear
local
signal
local
preferenti
nucleu
similar
high
date
select
substrat
inhibitor
distinguish
enzym
found
hamper
search
individu
function
knockout
model
describ
knockin
replac
activ
site
serin
alanin
prove
lethal
neonat
die
within
hour
birth
analysi
gene
express
pattern
knockin
mice
show
differenti
express
gene
involv
cell
growth
innat
immun
metabol
pathway
dpp
activ
abl
cleav
substrat
vitro
although
lower
rate
physiolog
relev
cleavag
extracellular
peptid
clear
consid
cytoplasm
locat
shown
ratelimit
degrad
prolinecontain
peptid
involv
antigen
present
proteom
studi
use
termin
amin
isotop
label
substrat
approach
identifi
sever
substrat
includ
calreticulin
adenyl
kinas
provid
possibl
lead
function
role
involv
adipogenesi
also
suggest
sinc
select
result
impair
adipocyt
differenti
inhibitor
exert
antiinflammatori
effect
human
well
murin
activ
macrophag
studi
impli
involv
cell
migrat
apoptosi
cell
adhes
identifi
interact
partner
demonstr
sumoyl
protein
alloster
regul
activ
anoth
recent
identifi
interact
partner
filamin
recruit
syk
import
compon
bcell
receptor
signal
syk
cleav
henc
influenc
stabil
syk
enzym
wide
express
found
cell
immun
system
epithelia
endothelia
brain
reproduct
organ
other
fap
also
known
sepras
type
ii
membran
protein
first
describ
solubl
form
fap
found
blood
sourc
circul
fap
current
known
fap
dpp
activ
addit
also
possess
endopeptidas
gelatinas
activ
fap
endopeptidas
activ
restrict
cleav
intern
pro
preced
gli
known
substrat
repertoir
fap
limit
includ
denatur
collagen
vitro
work
identifi
sever
substrat
neuropeptid
substanc
p
btype
natriuret
peptid
also
fap
substrat
believ
fap
larg
absent
healthi
adult
tissu
express
embryogenesi
inflamm
wound
heal
cancer
fibrosi
howev
recent
report
show
fap
normal
condit
high
express
skin
pancrea
endometrium
addit
fap
knockout
mous
model
affect
embryon
develop
normal
organ
function
epitheli
cancer
fap
local
reactiv
stromal
fibroblast
also
detect
certain
sarcoma
absenc
fap
major
normal
cell
tissu
restrict
express
cancer
make
fap
interest
target
select
deliveri
cytotox
compound
tumor
site
addit
target
fap
also
focu
anticanc
research
sinc
implic
extracellular
matrix
remodel
gelatinas
activ
antitumor
immun
process
substrat
regardless
exact
role
fap
appear
highli
depend
tumor
microenviron
cancer
type
prep
also
call
prolyl
endopeptidas
discov
oxytocin
cleav
enzym
uteru
contrast
describ
enzym
prep
endopeptidas
activ
high
express
prep
found
brain
subject
sever
studi
prep
cytoplasm
enzym
activ
also
measur
bodi
fluid
short
peptid
amino
acid
long
contain
prolin
possibl
substrat
prep
research
done
vitro
exampl
substrat
substanc
p
angiotensin
ii
bradykinin
prep
involv
gener
prolineglycineprolin
pgp
collagen
fragment
pgp
neutrophil
chemoattract
import
player
neutrophil
inflamm
sinc
prep
also
present
neutrophil
also
play
role
sustain
neutrophil
inflamm
link
prep
patholog
mani
lung
diseas
prep
involv
synthesi
antifibrot
peptid
nacetylserylaspartyllysylprolin
shown
prep
interact
acceler
aggreg
addit
interact
partner
dehydrogenas
growthassoci
protein
tubulin
suggest
function
prep
role
protein
process
secret
axon
transport
discoveri
prolin
specif
dpp
uncov
problem
literatur
sinc
report
activ
often
support
gene
protein
express
analysi
use
antibodi
protein
detect
immunoassay
one
keep
mind
enzym
share
structur
properti
antibodi
may
crossreact
likewis
overlap
substrat
specif
complic
interpret
enzymat
activ
assay
situ
vitro
consequ
techniqu
often
also
reagent
believ
specif
past
turn
identifi
measur
multipl
enzym
certainli
case
dpp
fap
prep
enzym
assay
synthet
substrat
exampl
glyproparanitroanilid
pna
cleav
benzylcarboxi
z
glypropna
zglyproamc
substrat
fap
prep
addit
inhibitor
use
past
even
use
clinic
today
differ
select
toward
famili
member
therefor
research
care
interpret
data
literatur
predat
discoveri
enzym
addit
design
new
experi
one
awar
specif
lack
thereof
reagent
method
use
warn
mind
literatur
search
report
express
individu
enzym
human
lung
health
diseas
search
term
includ
asthma
chronic
obstruct
pulmonari
diseas
copd
lung
cancer
fibrosi
ischemia
reperfus
injuri
iri
pneumonia
relev
data
appear
avail
anim
model
incorpor
well
inform
review
uptod
octob
express
prolinespecif
enzym
lung
health
diseas
identifi
function
receptor
middl
east
respiratori
syndrom
coronaviru
b
e
e
r
u
n
e
r
n
h
e
pathogenesi
merscov
distribut
human
respiratori
tract
investig
use
immunohistochemistri
ihc
antibodi
clone
epithelium
nasal
mucosa
conduct
airway
rare
observ
although
could
detect
small
subset
goblet
cell
noncili
cell
ciliat
cell
airway
trend
higher
immunostain
smaller
airway
also
present
mononuclear
leukocyt
mainli
tlymphocyt
submucos
gland
serou
cell
mucou
cell
parenchyma
detect
type
ii
cell
alveolar
macrophag
endothelium
pulmonari
vessel
also
stain
decreas
stain
intens
lymphat
venul
arteriol
result
line
investig
use
enzym
histochemistri
ihc
antibodi
evalu
distribut
human
bronchu
report
stain
blood
vessel
seros
gland
leukocyt
bronchial
epithelium
smooth
muscl
connect
tissu
neg
anoth
ihc
studi
antibodi
clone
reveal
similar
result
report
nasal
mucosa
describ
antibodi
clone
submucos
seromuc
gland
leukocyt
endotheli
cell
venul
capillari
epitheli
cell
activ
shown
measur
bronchoalveolar
lavag
bal
fluid
increas
bal
fluid
patient
includ
tumor
sarcoidosi
infecti
diseas
aid
activ
higher
number
lymphocyt
increas
strict
correl
might
impli
bal
fluid
partial
origin
sourc
activ
measur
glypropna
lower
bronchial
epitheli
cell
line
alveolar
epitheli
cell
line
turn
lower
primari
bal
macrophag
schade
et
al
also
measur
activ
glypropna
bal
fluid
collect
rat
low
activ
like
repres
could
measur
bal
fluid
rat
account
approxim
total
activ
measur
rat
wildtyp
rat
express
activ
mainli
found
lung
parenchyma
less
bronchi
activ
express
locat
bronchi
leukocyt
weakli
parenchyma
express
inact
member
dpp
famili
also
detect
bronchi
leukocyt
lavag
lung
result
lower
express
lung
sinc
differenti
express
lung
activ
measur
cell
might
fact
repres
also
mrna
express
demonstr
human
bronchial
epitheli
cell
transform
bronchial
epitheli
cell
cell
line
cell
howev
cell
line
origin
cancer
tissu
cell
might
repres
correspond
primari
airway
epitheli
cell
vivo
sinc
sever
reason
potenti
role
asthma
name
function
costimulatori
molecul
abil
process
substrat
involv
asthma
interact
protein
alreadi
extens
studi
variou
asthma
model
inform
asthma
reader
refer
recent
review
nietofontarigo
et
al
schade
et
al
induc
asthma
rat
sensit
challeng
ovalbumin
result
increas
total
bal
fluid
respons
approxim
one
fifth
total
activ
addit
increas
express
activ
detect
parenchyma
bronchi
express
also
upregul
asthma
induct
gene
previous
identifi
suscept
marker
asthma
sensit
challeng
differ
concentr
ovalbumin
rat
result
dosedepend
increas
cell
lung
contrast
subsequ
studi
signific
differ
determin
glypropna
could
found
bal
fluid
van
der
velden
et
al
see
differ
number
cell
bronchial
epithelium
healthi
control
patient
asthma
patient
treat
inhal
receiv
corticosteroid
month
prior
studi
author
could
also
detect
differ
determin
glypropna
bal
fluid
nonsmok
smoker
asthma
patient
treatment
inhal
fluticason
propion
week
alter
activ
bal
fluid
shiobara
et
al
demonstr
increas
mrna
express
bronchial
epitheli
cell
distal
airway
asthma
patient
use
ihc
bronchial
biopsi
protein
express
shown
bronchial
epitheli
cell
inflammatori
cell
eosinophil
macrophag
lymphocyt
patient
corticosteroidtr
patient
stain
reduc
stimul
bronchial
epitheli
cell
result
increas
mrna
protein
express
meyerholz
et
al
studi
influenc
tissu
remodel
distribut
lung
patient
copd
cystic
fibrosi
signific
increas
immunostain
found
type
ii
cell
alveolar
macrophag
lung
patient
alveolar
macrophag
show
stronger
stain
activ
also
hypertrophi
mesotheli
cell
often
correspond
increas
stain
gene
chromosom
identifi
novel
risk
locu
fibrot
idiopath
interstiti
pneumonia
ipf
case
express
mrna
wholelung
sampl
higher
control
also
fap
shown
upregul
ipf
patient
use
ihc
fap
antibodi
immunoreact
could
detect
tissu
bronchiolar
epithelium
type
ii
pneumocyt
endothelium
smooth
muscl
alveolar
macrophag
normal
lung
centriacinar
emphysema
case
studi
could
also
detect
antibodi
tissu
except
posit
cell
alveolar
epithelium
contrast
result
meyerholz
et
al
contrari
fap
express
high
fibroblast
foci
identifi
could
seen
h
e
stain
section
fibrot
interstitium
suggest
potenti
role
fap
extracellular
matrix
modif
show
distinct
express
pattern
stain
hyperplast
alveolar
line
cell
overli
fibroblast
foci
fibroblast
foci
induct
pulmonari
fibrosi
bleomycin
thorac
irradi
murin
model
result
increas
fap
mrna
express
also
confirm
immunostain
stromal
cell
rather
inflammatori
cell
alveolar
epitheli
cell
induct
pulmonari
fibrosi
fapdefici
mice
result
decreas
surviv
increas
lung
collagen
content
model
due
chang
activ
matrix
metalloproteinas
mmp
suggest
fap
antifibrot
effect
lung
fap
process
mmpdegrad
collagen
improv
intern
clearanc
collagen
macrophag
fibroblast
state
prep
pgp
gener
collagen
chemotact
effect
neutrophil
base
substrat
specif
fap
also
abl
produc
pgp
mmpprocess
collagen
henc
might
also
exert
effect
mechan
howev
hypothesi
need
explor
lung
tissu
activ
smoker
copd
patient
prep
highli
express
neutrophil
macrophag
epitheli
cell
number
inflammatori
cell
prep
express
lower
lung
tissu
exsmok
data
line
studi
mice
prep
activ
measur
zglyproamc
lung
homogen
higher
cigarett
smokeexpos
mice
immunohistochem
analysi
show
prep
epitheli
cell
control
mice
smokeexpos
mice
protein
express
prep
increas
due
influx
inflammatori
cell
macrophag
neutrophil
highli
express
prep
prep
activ
measur
sputum
zglypropna
time
higher
patient
cystic
fibrosi
compar
healthi
control
prep
mrna
protein
express
enzymat
activ
shown
multipl
airway
epitheli
cell
cell
line
primari
cell
prep
could
found
medium
cystic
fibrosi
bronchial
epitheli
cell
increas
stimul
lipopolysaccharid
lp
without
increas
prep
mrna
deplet
tolllik
receptor
result
attenu
lpsinduc
releas
prep
report
prep
releas
airway
epitheli
cell
exosom
sputum
patient
cystic
fibrosi
colon
pseudomona
aeruginosa
show
exosom
increas
prep
protein
express
two
main
group
lung
cancer
small
cell
lung
cancer
sclc
nonsmal
cell
lung
cancer
nsclc
nsclc
account
approxim
case
common
type
nsclc
adenocarcinoma
larg
cell
carcinoma
squamou
cell
carcinoma
evalu
activ
base
differ
lung
carcinoma
reveal
posit
stain
case
adenocarcinoma
squamou
cell
carcinoma
small
cell
carcinoma
larg
cell
carcinoma
carcinoid
neg
studi
differ
nsclc
cell
line
comparison
normal
bronchial
epitheli
cell
show
lower
enzymat
activ
protein
mrna
express
et
al
use
glyproamc
studi
succinylglyproamc
prep
differ
lung
tumor
contrast
previou
report
show
higher
activ
enzym
squamou
cell
carcinoma
adenocarcinoma
compar
match
lung
parenchyma
dimitrova
et
al
use
new
fluorogen
substrat
name
glyprohydrazido
detect
studi
human
fetal
lungderiv
cell
specif
substrat
valid
inhibitor
n
hphepro
hydroxylamin
report
result
abolish
enzymat
activ
problem
inhibitor
character
research
awar
exist
might
well
inhibit
multipl
famili
member
take
uncertainti
account
fluoresc
intens
lower
tumor
cell
line
compar
fetal
cell
confirm
enzymat
activ
measur
glypropna
howev
comparison
fetal
cancer
tissu
might
optim
sinc
shown
activ
higher
human
fetal
lung
compar
adult
lung
rel
surfac
activ
surfac
activ
versu
total
activ
fetal
cell
almost
indic
present
membran
instead
rel
surfac
activ
cell
mean
two
third
activ
locat
intracellularli
author
explain
disturb
intracellular
membran
transport
system
possibl
contribut
intracellular
enzym
neglect
silico
analysi
show
fap
mrna
express
upregul
squamou
cell
carcinoma
larg
cell
carcinoma
adenocarcinoma
compar
normal
lung
tissu
ihc
antibodi
confirm
fap
restrict
stroma
epitheli
cancer
fap
immunostain
antibodi
abcam
tumor
tissu
patient
nsclc
demonstr
posit
stromal
stain
case
higher
express
fap
associ
wors
surviv
talabostat
also
known
valboropro
inhibitor
dpp
includ
fap
phase
ii
trial
talabostat
docetaxel
advanc
nsclc
show
enhanc
clinic
activ
patient
malign
pleural
mesothelioma
mpm
protein
highli
express
weak
express
seen
adenomatoid
tumor
reactiv
mesotheli
cell
activ
protein
express
also
detect
pleural
fluid
patient
epithelioid
subtyp
mpm
level
substrat
glypropna
increas
compar
patient
benign
pleural
diseas
mpm
patient
sarcomat
subtyp
significantli
increas
pleural
fluid
higher
reach
statist
signific
protein
level
pleural
effus
pe
significantli
higher
malign
nsclc
paramalign
nsclc
pneumonia
patient
compar
tuberculosi
patient
studi
also
shown
protein
level
activ
measur
glypropna
higher
pe
patient
tuberculosi
compar
nontubercul
pe
includ
malign
heart
failur
parapneumon
effus
prep
activ
measur
zglyprosulfamethoxazol
healthi
lung
tissu
patient
lung
carcinoma
bal
fluid
patient
variou
lung
diseas
prep
could
detect
supernat
bal
fluid
well
cell
pellet
centrifug
higher
enzymat
activ
pellet
seen
higher
cell
count
percentag
macrophag
prep
determin
bal
fluid
lung
transplant
patient
use
zglypropna
substrat
antibodi
target
synthet
peptid
repres
residu
murin
prep
protein
express
enzymat
activ
higher
patient
bronchiol
obliteran
syndrom
time
diagnosi
compar
acut
reject
reject
match
sampl
month
diagnosi
role
iri
also
extens
studi
multipl
model
includ
lung
review
matheeussen
et
al
howev
studi
main
focu
lie
effect
pharmacolog
inhibit
less
express
pattern
enzym
cover
review
best
knowledg
inform
express
lung
iri
model
avail
pneumonia
anoth
search
term
employ
review
unfortun
nt
abl
retriev
inform
express
enzym
infecti
pneumonia
one
abstract
show
possibl
role
fap
host
respons
bacteri
infect
clinic
use
theoret
suspect
increas
risk
pneumonia
base
involv
immun
system
howev
sever
recent
studi
abl
identifi
associ
literatur
review
clear
far
best
character
member
prep
famili
healthi
diseas
lung
less
data
found
enzym
n
h
e
l
h
l
u
n
g
p
p
w
r
e
p
r
e
n
l
u
n
g
parenchyma
immun
cell
endotheli
cell
submucos
gland
certain
case
also
detect
bronchial
epitheli
cell
implic
asthma
differ
studi
corrobor
term
possibl
differenti
express
asthma
avail
data
lung
cancer
cancer
gener
often
conflict
certain
studi
show
decreas
express
activ
other
report
opposit
comparison
studi
howev
hinder
use
wide
variat
method
tissu
type
cell
line
express
activ
pleural
fluid
investig
multipl
studi
possibl
biomark
unfortun
result
also
unambigu
probabl
best
marker
pleural
fluid
differenti
differ
lung
diseas
express
lung
data
rat
asthma
model
current
avail
show
activ
express
bronchi
leukocyt
increas
asthma
induct
also
copd
cystic
fibrosi
ipf
enzym
studi
shown
increas
prep
detect
epitheli
cell
normal
lung
highli
express
inflammatori
cell
differ
lung
patholog
limit
studi
fap
show
express
normal
lung
fap
increas
sever
lung
cancer
shown
express
stroma
conclus
still
lot
miss
inform
express
prolinespecif
peptidas
healthi
diseas
lung
publish
data
often
appear
conflict
appli
method
diver
specif
use
assay
question
beg
welldesign
research
knowledg
loss
gain
protein
express
activ
diseas
might
tie
enzym
certain
cell
type
substrat
interact
partner
involv
pathophysiolog
diseas
ultim
lead
elucid
function
role
appar
differenti
express
enzym
lung
diseas
make
interest
candid
valid
biomark
